Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors

International Journal of Clinical Oncology

Volumn 16, Issue 6, 2011, Pages 741-745

  Kikuchi, Hirotoshi ^a   Setoguchi, Tomohiko ^a   Miyazaki, Shinichiro ^a   Yamamoto, Masayoshi ^a   Ohta, Manabu ^a   Kamiya, Kinji ^a   Sakaguchi, Takanori ^a   Konno, Hiroyuki ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

GIST; Imatinib; Mutation; Secondary resistance; Sunitinib

Indexed keywords

GENOMIC DNA; IMATINIB; SUNITINIB;

AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER RESISTANCE; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SENSITIVITY; EXON; GASTROINTESTINAL STROMAL TUMOR; GENE DELETION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOTHYROIDISM; INTERVENTION STUDY; LIVER RESECTION; LIVER TUMOR; LOBECTOMY; MALE; ONCOGENE C KIT; PERITONEUM TUMOR; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT DURATION;

AGED; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HEPATECTOMY; HUMANS; INDOLES; LIVER NEOPLASMS; MALE; MUTATION; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; PYRROLES;

EID: 84855197373     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0208-4     Document Type: Article

References (30)

1. S Hirota K Isozaki Y Moriyama, et al. 1998 Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 577 580 9438854 10.1126/science.279.5350.577 1:CAS:528:DyaK1cXotVyhsw%3D%3D (Pubitemid 28067289)
2. S Hirota A Ohashi T Nishida, et al. 2003 Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors Gastroenterology 125 660 667 12949711 10.1016/S0016-5085(03)01046-1 1:CAS:528:DC%2BD3sXnvVSiur8%3D (Pubitemid 37070684)
3. MC Heinrich CL Corless A Duensing, et al. 2003 PDGFRA activating mutations in gastrointestinal stromal tumors Science 299 708 710 12522257 10.1126/science.1079666 1:CAS:528:DC%2BD3sXntFWitQ%3D%3D (Pubitemid 36159485)
4. ML Lux BP Rubin TL Biase, et al. 2000 KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors Am J Pathol 156 791 795 10702394 10.1016/S0002-9440(10)64946-2 1:CAS:528:DC%2BD3cXitVerur0%3D (Pubitemid 30626936)
5. BP Rubin S Singer C Tsao, et al. 2001 KIT activation is a ubiquitous feature of gastrointestinal stromal tumors Cancer Res 61 8118 8121 11719439 1:CAS:528:DC%2BD3MXovVShs7w%3D (Pubitemid 33091601)
6. S Hirota T Nishida K Isozaki, et al. 2001 Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours J Pathol 193 505 510 11276010 10.1002/1096-9896(2000)9999:9999<::AID-PATH818>3.0.CO;2- E 1:CAS:528:DC%2BD3MXivVGrsbs%3D (Pubitemid 32266820)
7. E Buchdunger CL Cioffi N Law, et al. 2000 Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors J Pharmacol Exp Ther 295 139 145 10991971 1:CAS:528:DC%2BD3cXnt1ygur4%3D
8. H Joensuu PJ Roberts M Sarlomo-Rikala, et al. 2001 Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor N Engl J Med 344 1052 1056 11287975 10.1056/NEJM200104053441404 1:STN:280:DC%2BD3M3gvVekuw%3D%3D (Pubitemid 32267975)
9. AT van Oosterom I Judson J Verweij, et al. 2001 Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study Lancet 358 1421 1423 11705489 10.1016/S0140-6736(01)06535-7 (Pubitemid 33055745)
10. E Tamborini L Bonadiman A Greco, et al. 2004 A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient Gastroenterology 127 294 299 15236194 10.1053/j.gastro.2004.02.021 1:CAS:528:DC%2BD2cXmsVShsL8%3D (Pubitemid 38962296)
11. LL Chen JC Trent EF Wu, et al. 2004 A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors Cancer Res 64 5913 5919 15342366 10.1158/0008-5472.CAN-04-0085 1:CAS:528:DC%2BD2cXntFClsr4%3D (Pubitemid 39129383)
12. CR Antonescu P Besmer T Guo, et al. 2005 Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation Clin Cancer Res 11 4182 4190 15930355 10.1158/1078-0432.CCR-04-2245 1:CAS:528:DC%2BD2MXks1GksLw%3D (Pubitemid 40791584)
13. Heinrich MC, Maki RG, Corless CL et al (2006) Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. J Clin Oncol 24(Suppl):9502
14. GD Demetri AT van Oosterom CR Garrett, et al. 2006 Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 1329 1338 17046465 10.1016/S0140-6736(06)69446-4 1:CAS:528:DC%2BD28XhtVOrtL%2FL (Pubitemid 44528723)
15. H Kikuchi K Yamashita T Kawabata, et al. 2006 Immunohistochemical and genetic features of gastric and metastatic liver gastrointestinal stromal tumors: sequential analyses Cancer Sci 97 127 132 16441423 10.1111/j.1349-7006. 2006.00154.x 1:CAS:528:DC%2BD28XitFyqsLo%3D (Pubitemid 43379480)
16. RP DeMatteo JJ Lewis D Leung, et al. 2000 Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival Ann Surg 231 51 58 10636102 10.1097/00000658-200001000-00008 1:STN:280: DC%2BD3c7gtVSmtQ%3D%3D (Pubitemid 30043939)
17. PJ Roberts B Eisenberg 2002 Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease Eur J Cancer 38 Suppl 5 S37 S38 12528771 10.1016/S0959-8049(02)80601-3
18. GS Papaetis KN Syrigos 2009 Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies BioDrugs 23 377 389 19894779 10.2165/11318860-000000000-00000 1:CAS:528:DC%2BC3cXhtF2qs7g%3D
19. KS Gajiwala JC Wu J Christensen, et al. 2009 KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients Proc Natl Acad Sci USA 106 1542 1547 19164557 10.1073/pnas.0812413106 1:CAS:528:DC%2BD1MXhvVOms78%3D
20. T Nishida T Takahashi A Nishitani, et al. 2009 Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene Int J Clin Oncol 14 143 149 19390946 10.1007/s10147-008-0822-y 1:CAS:528:DC%2BD1MXkvFeqtb4%3D
21. W Ruka P Rutkowski A Szawlowski, et al. 2009 Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib Eur J Surg Oncol 35 87 91 18289826 10.1016/j.ejso.2008.01.003 1:STN:280:DC%2BD1M%2FgtVajtA%3D%3D
22. CP Raut Q Wang J Manola, et al. 2010 Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate Ann Surg Oncol 17 407 415 19898902 10.1245/s10434-009-0784-y
23. MA Pantaleo M Di Battista F Catena, et al. 2008 Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib? J Cancer Res Clin Oncol 134 625 630 18202855 10.1007/s00432-007-0347-1 1:CAS:528:DC%2BD1cXjsF2ju78%3D
24. GD Demetri M von Mehren CR Antonescu, et al. 2010 NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors J Natl Comp Canc Netw 8 Suppl 2 S1 S41 1:CAS:528:DC%2BC3cXlvFOls7g%3D
25. RP DeMatteo RG Maki S Singer, et al. 2007 Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor Ann Surg 245 347 352 17435539 10.1097/01.sla.0000236630.93587.59 (Pubitemid 46673128)
26. CP Raut M Posner J Desai, et al. 2006 Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors J Clin Oncol 24 2325 2331 16710031 10.1200/JCO.2005.05. 3439 1:CAS:528:DC%2BD28XlvV2ksbw%3D (Pubitemid 46630664)
27. A Gronchi M Fiore F Miselli, et al. 2007 Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST Ann Surg 245 341 346 17435538 10.1097/01.sla. 0000242710.36384.1b (Pubitemid 46673127)
28. MC Heinrich CL Corless CD Blanke, et al. 2006 Molecular correlates of imatinib resistance in gastrointestinal stromal tumors J Clin Oncol 24 4764 4774 16954519 10.1200/JCO.2006.06.2265 1:CAS:528:DC%2BD28XhtFynsrrN (Pubitemid 46630941)
29. E Wardelmann S Merkelbach-Bruse K Pauls, et al. 2006 Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate Clin Cancer Res 12 1743 1749 16551858 10.1158/1078-0432.CCR-05-1211 1:CAS:528:DC%2BD28Xis1Cjs7Y%3D
30. KH Lim MJ Huang LT Chen, et al. 2008 Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors Med Oncol 25 207 213 18488160 10.1007/s12032-007-9014-2 1:CAS:528:DC%2BD1cXotVOgtbY%3D